Status:
COMPLETED
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
Lead Sponsor:
AstraZeneca
Conditions:
Pain
Eligibility:
MALE
35-50 years
Phase:
PHASE1
Brief Summary
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.
Eligibility Criteria
Inclusion
- Provision of signed informed consent
- Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG.
Exclusion
- History of somatic disease/condition, which may interfere with the objectives of the study.
- History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder.
- Healthy volunteers who have been exposed to radiation levels above background (eg, through X-ray examinations).
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00829088
Start Date
January 1 2009
End Date
February 1 2009
Last Update
February 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cheshire, United Kingdom